Develops drugs and genomic tests for esophageal cancer and other diseases.
Jun 2026Revenue $3.85M/yrExpenses $19.4M/yr
No trendCash runway ≈ 1 months from Jun 2026
Figures by year
When will ProPhase Labs be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $3.85M and expenses $19.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $4.34M | $22.4M | −$18.0M |
| Dec 2024 | $6.77M | $45.4M | −$38.6M |
| Dec 2023 | $35.0M | $56.2M | −$21.2M |
| Dec 2022 | $123M | $99.1M | $23.6M |
| Dec 2021 | $79.0M | $69.2M | $9.80M |
| Dec 2020 | $14.5M | $16.6M | −$2.08M |
| Dec 2019 | $9.88M | $13.1M | −$3.24M |
| Dec 2018 | $13.1M | $14.8M | −$1.63M |
| Dec 2017 | $9.87M | $13.9M | −$3.99M |
| Dec 2016 | $4.21M | $6.86M | −$2.66M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.